In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 10, 2003, Pages 3260-3269

  Nilius, Angela M ^a   Shen, Linus L ^a   Hensey Rudloff, Dena ^a   Almer, Laurel S ^a   Beyer, Jill M ^a   Balli, Darlene J ^a   Cai, Yingna ^a   Flamm, Robert K ^a,b  

^a ABBOTT LABORATORIES   (United States)

^b Focus Technologies Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; AMINO ACID; ANTIINFECTIVE AGENT; AZETIDINE DERIVATIVE; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DNA TOPOISOMERASE IV; LEVOFLOXACIN; NAPHTHYRIDINE DERIVATIVE; OFLOXACIN; PLASMA PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANAEROBIC BACTERIUM; ANIMAL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CHEMISTRY; CHLAMYDIA TRACHOMATIS; CITROBACTER FREUNDII; COMMUNICABLE DISEASE; COMPARATIVE STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; ENTEROBACTERIACEAE; ENZYME INHIBITION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; HOSPITAL INFECTION; HUMAN; LEGIONELLA; LUNG INFECTION; METABOLISM; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MORAXELLA CATARRHALIS; NEISSERIA GONORRHOEAE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; RAT; RESPIRATORY TRACT INFECTION; SERRATIA MARCESCENS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BLOOD PROTEINS; CIPROFLOXACIN; DNA TOPOISOMERASES, TYPE II, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; OFLOXACIN; PROTEIN BINDING; QUINOLONES; RATS;

EID: 0141993979     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.10.3260-3269.2003     Document Type: Article

References (40)

1. Almer, L. S., V. D. Shortridge, A. M. Nilius, N. B. Soni, J. M. Beyer, G. G. Stone, and R. K. Flamm. 2002. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 43:225-232.
2. Biedenbach, D. J., and R. N. Jones. 2000. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY Antimicrobial Surveillance Program (North and Latin America). Diagn. Microbiol. Infect. Dis. 36:255-259.
3. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
4. Brueggemann, A. B., S. L. Coffman, P. Rhomberg, H. Huynh, L. Almer, A. Nilius, R. Flamm, and G. V. Doern. 2002. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46:680-688.
5. Chen, D. K., A. McGreer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.
6. Clement, J. J., S. K. Tanaka, J. Alder, C. Vojtko, J. Beyer, D. Hensey, N. Ramer, D. McDaniel, and D. T. W. Chu. 1994. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Antimicrob. Agents Chemother. 38:1071-1078.
7. Doern, G. V., A. B. Brueggemann, G. Pierce, T. Hogan, H. P. Holley, Jr., and A. M. Rauch. 1996. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40:2884-2886.
8. Doern, G. V., A. B. Brueggemann, G. Pierce, G. H. P. Holley, Jr., and A. M. Rauch. 1996. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 to 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 41:292-297.
9. Doern, G. V., K. P. Heilmann, H. K. Huynh, P. R. Rhomberg, S. L. Coffman, and A. B. Breuggemann. 2001. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45:1721-1729.
10. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
11. Dutka-Malen, S., S. Evers, and P. Courvalin. 1995. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 33:24-27.
12. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
13. Fournier, B., X. Zhao, T. Lu, K. Drlica, and D. C. Hooper. 2000. Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob. Agents Chemother. 44:2160-2165.
14. Gootz, T. D., and K. E. Brighty. 1996. Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects. Med. Res. Rev. 16: 433-486.
15. Gump, D. W. 1996. Antimicrobial susceptibility testing for some atypical microorganisms: chlamydiae, mycoplasmas, Rickettsia, and spirochetes, p. 212-229. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
16. Herold, B. C., L. C. Immergluck, M. C. Maranan, D. S. Lauderdale, R. E. Gaskin, S. Boyle-Vavra, C. D. Leitch, and R. S. Daum. 1998. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279:593-598.
17. Hoban, D. J., G. V. Doern, A. C. Fluit, M. Roussel-Delvallez, and R. N. Jones. 2001. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32: S81-S93.
18. Ho, P.-L., T.-L. Que, D.-C. Tsang, T.-K. Ng, K.-H. Chow, and W.-H. Seto. 1999. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. 43:1310-1313.
19. Ho, P.-L., R. W. H. Yung, D.-C. Tsang, T.-L. Que, M. Ho, W.-H. Seto, T.-K. Ng, W. C. Yam, and W. W. S. Ng. 2001. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 48:659-665.
20. Hooper, D. C. 2000. New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. 30:243-254.
21. Johnson, S. E., G. C. Klein, G. P. Schmid, and J. C. Feeley. 1984. Susceptibility of the Lyme disease spirochete to seven antimicrobial agents. Yale J. Biol. Med. 57:549-553.
22. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094.
23. Madhusudan, K., and V. Nagaraja. 1996. Alignment and phylogenetic analysis of type II DNA topoisomerases. J. Biosci. 21:613-629.
24. Margerrison, E. E., R. Hopewell, and L. M. Fischer. 1992. Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J. Bacteriol. 174:1596-1603.
25. National Committee for Clinical Laboratory Standards. 1992. Methods for determining bactericidal activity of antimicrobial agents. Tentative guideline M26-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
26. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
27. National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing; ninth informational supplement. Approved standard M100-S11. National Committee for Clinical Laboratory Standards, Wayne, Pa.
28. Pan, X., and L. M. Fisher. 1996. Cloning and characterization of the parC and pare genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178:4060-4069.
29. Pan, X.-S., and L. M. Fisher. 1998. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2810-2816.
30. Saiki, A. Y. C., L. L. Shen, C.-M. Chen, J. Baranowski, and C. G. Lerner. 1999. DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones. Antimicrob. Agents Chemother. 43:1574-1577.
31. Schmitz, F.-J., A. C. Fuit, S. Brisse, J. Verhoef, K. Köhrer, and D. Milatovic. 1999. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol. Med. Microbiol. 26:281-287.
32. Segreti, J., H. A. Kessler, K. S. Kapell, and G. M. Trenholme. 1989. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. Antimicrob. Agents Chemother. 31:100-101.
33. Shen, L. L., J. Baranowski, J. Fostel, D. A. Montgomery, and P. A. Lartey. 1992. DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob. Agents Chemother. 36:2778-2784.
34. Shortridge, V. D., G. V. Doern, A. B. Brueggemann, J. M. Beyer, and R. K. Flamm. 1999. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin. Infect. Dis. 29: 1186-1188.
35. Shortridge, V. D., R. K. Flamm, N. Ramer, J. Beyer, and S. K. Tanaka. 1996. Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 26:73-78.
36. Stone, G. G., D. Shortridge, R. K. Flamm, J. Versalovic, J. Beyer, K. Idler, L. Zulawinski, and S. K. Tanaka. 1996. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. Helicobacter 1:227-228.
37. Swenson, J. M., C. Thornsberry, and V. A. Silcox. 1982. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob. Agents Chemother. 22:186-192.
38. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510.
39. Wexler, H. M., and S. M. Finegold. 1991. Antibacterial susceptibility tests: anaerobic bacteria, p. 1133-1137. In A. Balows, W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
40. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996.